Cases
Each patient had longstanding rheumatoid arthritis, was taking azathioprine, and had previously been diagnosed as having asymptomatic fibrosing alveolitis. Sudden onset of breathlessness associated with deteriorating lung function occurred after three or fewer doses of infliximab. Extensive investigations did not find any infection or other cause for the respiratory decline. Details of the patients and investigation are shown in the table.
Comment
As the pathophysiology is unknown, we caution the use of infliximab in patients with underlying lung disease. An infection may have caused the deterioration despite lack of isolation of an organism. Vigilance is needed for all patients on immune modulating drugs. Conversely, progressive lung disease may be falsely attributed to an infection when the cause is an inflammatory or idiosyncratic reaction.
Two further cases of pneumonitis associated with infliximab as monotherapy have been reported: one patient with Crohn's disease, the other in a patient with ankylosing spondylitis.
1 2 Etanercept (a TNF receptor fusion protein; Enbrel, Wyeth) has also been linked with lung injury.
3 Cases have also recently been described of infliximab precipitating methotrexate pneumonitis. 4 Associations of pulmonary disease and all three licensed biological agents for rheumatoid arthritis-infliximab, etanercept, and adalimumab (a humanised monoclonal anti-TNF antibody; Humira, Abbott)-have been reported to the Medicines and Healthcare Products Regulatory Agency.
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